B
Beyond Air
Developing nitric oxide therapy products to improve lung function
About Beyond Air
Beyond Air is a clinical-stage medical device and biopharmaceutical company focused on developing innovative treatments for respiratory and other severe lung diseases using nitric oxide (NO). The company primarily serves healthcare providers and patients suffering from conditions such as Persistent Pulmonary Hypertension of the Newborn (PPHN), bronchiolitis, and nontuberculous mycobacteria (NTM) lung disease. Operating in the medical technology and biopharmaceutical markets, Beyond Air's business model revolves around the development, regulatory approval, and commercialization of its proprietary LungFit™ system. This system generates nitric oxide from ambient air, eliminating the need for high-pressure cylinders, thereby simplifying treatment administration and improving patient outcomes. Revenue is generated through the sale and licensing of its medical devices and related services.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- Kokhav Ya'ir Tsur Yig'al, Israel
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Avenue Capital Group- SCStreeterville Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beyond Air on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beyond Air on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.